Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

IP: Rafael Simó Canonge
Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Patricia Bogdanov Baruj, Andreea Ciudin Mihai, Ferran Casals Riera, Itziar Busquets Saez, Maddalen Zufiaurre Seijo, Enrique Franky Vargas, José Raul Herance Camacho, Ingrid Balcells Ortega, Marco Inzitari
Funding agency: EUROPEAN COMMISSION
Funding: 974782.7
Reference: RECOGNISED_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

"Estudi de la suceptibilitat genètica com a predictor de la pèrdua de pes i la resolució de les comorbiditats associades a l'obesitat després de cirurgía bariàtrica"

IP: Rafael Simó Canonge
Collaborators: Gemma Cuberas Borros
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 32160
Reference: SLT002/16/00497
Duration: 01/01/2017 - 31/12/2019

Grups de recerca en Diabetis i Metabolisme

IP: Rafael Simó Canonge
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 20000
Reference: 2017SGR01144
Duration: 12/04/2019 - 30/09/2021

Administración tópica de agonistas del receptor de GLP-1: una nueva estrategia para el tratamiento de la retinopatía deiabética

IP: Rafael Simó Canonge
Collaborators: Patricia Bogdanov Baruj
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 266200
Reference: SAF2016-77784-R
Duration: 30/12/2016 - 29/12/2019

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Raquel Rodríguez Gil

Raquel Rodríguez Gil

Main researcher
Multidisciplinary Nursing Research Group
Read more
Paula Isabel Roldan Caballero

Paula Isabel Roldan Caballero

Tècnic/a Superior Recerca
Academic Research Organisation (ARO)
Clinical Core Facilities
External Strategy Directorate
Read more
Martina Garriga Ferrer

Martina Garriga Ferrer

P Management and Admin. Project manager
External Strategy Directorate
Read more
Emily Betancourt Fernández

Emily Betancourt Fernández

Predoctoral researcher
Molecular Imaging and Therapy
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.